Stephen Carey Sells 2,850 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Stephen Carey sold 2,850 shares of the stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $72.80, for a total transaction of $207,480.00. Following the transaction, the chief financial officer directly owned 171,843 shares in the company, valued at $12,510,170.40. The trade was a 1.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Up 1.6%

Shares of ANI Pharmaceuticals stock opened at $73.06 on Thursday. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The firm has a market cap of $1.68 billion, a P/E ratio of 15.75 and a beta of 0.45. ANI Pharmaceuticals, Inc. has a fifty-two week low of $70.15 and a fifty-two week high of $99.50. The business has a 50-day moving average price of $79.12 and a 200 day moving average price of $78.53.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.ANI Pharmaceuticals’s quarterly revenue was up 25.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

ANIP has been the subject of a number of research reports. Guggenheim decreased their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Canaccord Genuity Group dropped their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $105.83.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System grew its holdings in shares of ANI Pharmaceuticals by 7,977.4% in the 2nd quarter. California State Teachers Retirement System now owns 1,983,574 shares of the specialty pharmaceutical company’s stock worth $164,200,000 after acquiring an additional 1,959,017 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock valued at $103,022,000 after purchasing an additional 27,598 shares during the period. State Street Corp increased its stake in ANI Pharmaceuticals by 2.2% in the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock worth $57,405,000 after purchasing an additional 15,496 shares in the last quarter. UBS Group AG increased its stake in ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its holdings in ANI Pharmaceuticals by 19.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company’s stock worth $43,399,000 after buying an additional 91,153 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.